Canada · Delayed Price · Currency is CAD NeuPath Health Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 11% revenue growth and 15% Adjusted EBITDA growth, with strong patient volume and capacity utilization gains. Expansion continues with a new Guelph facility and ongoing M&A activity, while gross margin faced pressure from higher staffing costs.
Fiscal Year 2025
-
Revenue grew 20% to CAD 87.2M in 2025, with adjusted EBITDA up 56% and margin improvement. Growth is driven by physician recruitment, technology, and service expansion, with 2026 guidance for 8%-12% revenue growth and higher EBITDA margin.
-
Q3 saw 26% revenue growth and a 98% increase in adjusted EBITDA, driven by higher patient volumes and operational improvements. The company reduced net debt, expanded in Alberta, and is actively pursuing acquisitions, with a strong cash position and ongoing share buybacks.